Get the Stockscreener App
1.38
6.15%
+0.08
Context Therapeutics Inc stock is currently priced at $1.38, with a 24-hour trading volume of 27,856.
It has seen a +6.15% increased in the last 24 hours and a +9.52% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $1.35 pivot point. If it approaches the $1.39 resistance level, significant changes may occur.
Previous Close:
$1.30
Open:
$1.32
24h Volume:
27,856
Market Cap:
$22.03M
Revenue:
-
Net Income/Loss:
$-23.96M
P/E Ratio:
-1.1795
EPS:
-1.17
Net Cash Flow:
$-21.05M
1W Performance:
-2.13%
1M Performance:
+9.52%
6M Performance:
+30.19%
1Y Performance:
+139.29%
1D Range:
$1.32
$1.38
52W Range:
$0.47
$1.69
Context Therapeutics Inc Stock (CNTX) Company Profile
Name
Context Therapeutics Inc
Sector
Industry
Phone
267 225 7416
Address
2001 Market Street, Suite 3915 Unit #15, Philadelphia
Context Therapeutics Inc Stock (CNTX) Latest News
Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers
GlobeNewswire Inc.
Context Therapeutics Reports Full Year 2023 Operating and Financial Results
GlobeNewswire Inc.
Why Quanex Building Products Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Benzinga
Constellation Energy, Battalion Oil And Other Big Stocks Moving Higher On Friday
Benzinga
Context Therapeutics Reports Third Quarter 2023 Operating and Financial Results
GlobeNewswire Inc.
Context Therapeutics Inc Stock (CNTX) Financials Data
Context Therapeutics Inc (CNTX) Net Income 2024
CNTX net income (TTM) was -$23.96 million for the quarter ending December 31, 2023, a -61.53% decrease year-over-year.
Context Therapeutics Inc (CNTX) Cash Flow 2024
CNTX recorded a free cash flow (TTM) of -$21.05 million for the quarter ending December 31, 2023, a -49.42% decrease year-over-year.
Context Therapeutics Inc (CNTX) Earnings per Share 2024
CNTX earnings per share (TTM) was -$1.50 for the quarter ending December 31, 2023, a -61.29% decline year-over-year.
About Context Therapeutics Inc
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for gynaecologic cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
3.08%
9.90%
Cap:
|
Volume (24h):